F-Prime Capital

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

Bluebird Kids Health is a pediatric healthcare provider that aims to build a healthier future for children. It offers a value-based care model, delivering comprehensive, evidence-based care tailored to each family's needs. Services include nutrition support, sleep training, treatments for common ailments like rashes and viruses, all aimed at reducing medical costs and providing personalized care. The company is also developing a proprietary technology platform, enhanced by AI, to proactively manage and coordinate treatment, further simplifying the experience for its clinical team.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Zenflow, Inc. is a medical device company focused on developing innovative solutions for urinary obstruction caused by benign prostatic hyperplasia (BPH) in men. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, Zenflow aims to address the significant unmet clinical need for effective and less invasive treatments. The company markets a unique spring device designed to relieve permanent BPH symptoms by gently propping open the urethra, thereby restoring its normal function while preserving the natural anatomy. This approach prioritizes patient experience, offering a treatment option that is less invasive and less painful compared to traditional methods. Zenflow is headquartered in San Francisco, California.

Based on our deep science and focused on patients in need.

Shift Bioscience is a biotechnology company focused on combating the diseases associated with aging through innovative cellular reprogramming techniques. The company has developed a high-throughput, high-accuracy aging biomarker, which is integrated into AI-driven simulations to identify safer gene factors for rejuvenation. By leveraging deep learning technology, Shift tests extensive gene combinations to discover potential drug candidates that can reverse aging and age-related diseases. The company's goal is to create a single family of drugs capable of addressing multiple age-related conditions, ultimately allowing for improved health and longevity through simple prescriptions.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

Metsera is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for obesity and metabolic conditions. The company focuses on advancing a variety of treatment options, including both oral and injectable therapies, specifically targeting incretin, non-incretin, and combination approaches. By integrating proprietary health technology tools, Metsera aims to provide personalized care that meets the evolving demands of weight loss treatment. Its commitment to addressing multiple therapeutic targets positions the company to significantly impact the future of obesity management and related metabolic diseases.

HiLabs is a developer of a healthcare data mining platform that aims to enhance data-driven decision-making within healthcare organizations. By leveraging artificial intelligence, HiLabs empowers employees to explore their data intuitively, uncover novel insights, and interact with data visualizations. The platform allows users to customize dashboards and generate new attributes, thus enhancing their ability to understand and utilize client health data effectively. HiLabs recognizes that healthcare providers possess vital domain knowledge but often lack the necessary tools to extract meaningful insights from their data. Through its innovative solutions, HiLabs bridges this gap, enabling healthcare organizations to harness their data more efficiently and improve overall decision-making processes.

Nocion Therapeutics, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, established in 2017. It specializes in developing innovative therapies known as "nocions," which are designed to treat conditions resulting from neurogenic inflammation. These therapies selectively target activated nociceptors, the sensory neurons responsible for pain perception, by utilizing small molecule charged sodium channel blockers. This targeted approach aims to provide robust and sustained relief from serious conditions such as cough, itch, pain, and inflammation, addressing the limitations of traditional small molecule anesthetics.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational siRNA medicine aimed at addressing preterm preeclampsia, a serious pregnancy complication. The company is committed to creating safe and effective treatment options that are both evidence-based and affordable, ensuring that all women and their infants can access necessary therapies for life-threatening conditions during pregnancy. By targeting the root causes of preeclampsia, Comanche Biopharma aspires to provide sustainable solutions that improve maternal and fetal health outcomes.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

OnCusp Therapeutics is a biopharmaceutical company dedicated to transforming advanced research into innovative cancer treatments. Founded by Bing Yuan, Eric Slosberg, and Andy Fu, the company focuses on accelerating the development of oncology medications to provide help and hope to cancer patients globally. OnCusp Therapeutics specializes in translating preclinical drug candidates into clinical proof-of-concept stages, aiming to swiftly advance these assets into early global clinical development.

PlasmaGen Biosciences Pvt. Ltd., established in 2010 and based in Bengaluru, India, is a biopharmaceutical company specializing in plasma protein therapies. The company manufactures a range of products including PlasmaGlob and AlbuMax, brands of Normal Human Immunoglobulin for Intravenous use, PlasmaRho-D I.V. for Rh immunization suppression, PlasmaRAB for rabies infection prophylaxis, PlasmaHep for hepatitis B exposure, VerBumin for conditions like hypovolemic shock and burns, and Gammafact-VIII. These products cater to various medical fields such as hematology, oncology, immunology, pediatrics, rheumatology, dermatology, and neurology. The company serves clinicians, medical practitioners, corporate hospitals, and government institutions.

Shinobi Therapeutics is a biotechnology company dedicated to developing innovative cell therapies that utilize hypoimmune CD8αβ induced pluripotent stem cells (iPS-T cells) to enhance cancer treatment and address other diseases. The company's advanced immune evasion technology aims to improve the effectiveness and accessibility of these therapies, ultimately reducing costs and enhancing patient outcomes. By focusing on durable responses and the potential for redosing, Shinobi Therapeutics strives to provide the healthcare industry with comprehensive immune therapies that can address a range of diseases, including cancer and genetic disorders.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative radiopharmaceuticals for cancer treatment. The company specializes in radioligand therapy, which utilizes alpha and beta emitters to target and disrupt the DNA of cancer cells. By creating a new class of alpha radioligand therapeutics, ARTBIO aims to enhance the effectiveness of cancer care and provide medical practitioners with novel therapeutic options. In addition to its drug development efforts, ARTBIO is dedicated to building a supportive ecosystem that maximizes the potential of its therapies, ultimately advancing the field of oncology.

T-Therapeutics is a biopharmaceutical company focused on developing engineered soluble biologics for oncological and immunological applications. The company utilizes a proprietary T cell receptor (TCR) discovery platform based on a highly humanized mouse model, which allows access to TCRs for human antigens that are typically unavailable from human samples. This innovative approach enables the binding of specific peptide-MHC (pMHC) targets on cells, facilitating the recruitment of T cells to combat cancer or modulate immune responses. Through its advanced capabilities in mouse genome engineering, single-cell genomics, machine learning, and structural biology, T-Therapeutics aims to enhance the quality of life for patients suffering from chronic and infectious diseases. The company's culture emphasizes creativity and collaboration, fostering an environment conducive to groundbreaking research and development in the biopharmaceutical field.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree connects pharmaceutical and healthcare brands with healthcare professionals (HCPs) through targeted advertising and data-driven solutions. The platform leverages artificial intelligence, data segmentation, and analytics to accurately identify and engage HCPs across various digital platforms, including physician networking sites and medical journals. By providing access to physician-only platforms, Doceree enables media agencies, pharmaceutical companies, medical device manufacturers, consumer healthcare brands, and hospitals to deliver compliant and effective messaging at scale.

Better Life Partners Inc. is a healthcare company based in Hanover, New Hampshire, dedicated to providing comprehensive support for individuals struggling with opioid use disorder in the United States. Established in 2018, the company offers a range of services, including medication-assisted treatment, counseling, peer coaching, and group sessions. Better Life Partners focuses on delivering personalized healthcare to vulnerable populations, utilizing technology to create customizable care plans that ensure effective and reliable service delivery. By integrating medical and behavioral healthcare, the company addresses the needs of those affected by addiction, facilitating their recovery through a combination of telehealth, community-based support, and innovative care approaches. With additional offices across New Hampshire, Better Life Partners aims to make a meaningful impact on the lives of individuals seeking to overcome substance abuse challenges.

K36 Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cancer treatment. The company specializes in translating epigenetic modulation of oncogenic pathways into effective therapies. By leveraging advanced technology, K36 Therapeutics creates orally bioavailable small molecules and selective inhibitors, aiming to enhance the treatment options available to healthcare professionals and improve outcomes for cancer patients.

ARTBIO is a clinical-stage biotechnology company focused on developing innovative radiopharmaceuticals for cancer treatment. The company specializes in radioligand therapy, which utilizes alpha and beta emitters to target and disrupt the DNA of cancer cells. By creating a new class of alpha radioligand therapeutics, ARTBIO aims to enhance the effectiveness of cancer care and provide medical practitioners with novel therapeutic options. In addition to its drug development efforts, ARTBIO is dedicated to building a supportive ecosystem that maximizes the potential of its therapies, ultimately advancing the field of oncology.

Comanche Biopharma is a biopharmaceutical company focused on developing an investigational siRNA medicine aimed at addressing preterm preeclampsia, a serious pregnancy complication. The company is committed to creating safe and effective treatment options that are both evidence-based and affordable, ensuring that all women and their infants can access necessary therapies for life-threatening conditions during pregnancy. By targeting the root causes of preeclampsia, Comanche Biopharma aspires to provide sustainable solutions that improve maternal and fetal health outcomes.

1upHealth, Inc. is a health data aggregation and centralization company based in Boston, Massachusetts, founded in 2017. It operates a platform that enables patients, providers, and software developers to securely aggregate and share medical data from various electronic medical record systems. The platform consolidates health data into a digital health record that users can control and share with healthcare providers. It facilitates real-time access to updated patient information across multiple health systems, enhancing the ability of providers to deliver informed care. Additionally, the platform automates secure data sharing from electronic medical records and wearable device metrics, allowing for improved healthcare outcomes through a trusted interoperability network.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.

Cadence Neuroscience, Inc. is an early-stage company founded in 2017 and headquartered in Redmond, Washington. It specializes in developing innovative medical device therapies aimed at treating epilepsy, central pain, and other neurological disorders. The company’s core technology, developed at the Mayo Clinic, is currently under clinical evaluation. Cadence Neuroscience's medical devices are designed to detect specific brain signals and deliver targeted electrical stimulation, allowing for tailored brain stimulation therapies. This approach enhances seizure control and aims to improve treatment outcomes for patients with neurological issues compared to existing protocols.

NOCD Inc. is a Chicago-based company founded in 2014 that specializes in developing a mobile application aimed at assisting individuals with obsessive-compulsive disorder (OCD). The platform connects users to licensed therapists who specialize in OCD through face-to-face video therapy sessions. Utilizing cognitive behavioral therapy techniques, the application guides users in self-treatment and monitoring of their symptoms, offering tools for exposure and response prevention exercises. In addition to therapy sessions, NOCD provides 24/7 support via self-help resources and peer communities, facilitating ongoing care and enabling patients to manage their condition effectively. The company focuses on improving treatment outcomes for OCD through its innovative online platform.

Enzene Biosciences is a biotechnology company focused on providing affordable medicines through the development of biosimilars. The company leverages advanced technologies and sophisticated analytics within its state-of-the-art manufacturing facilities to ensure cost-effective production. Enzene specializes in cloning, process development, and novel formulation development, enabling clients in the microbial manufacturing sector to adopt innovative solutions that improve healthcare outcomes. Additionally, the company aims to expand its reach and impact by forming strategic global alliances, while fostering a distinctive work culture that positions it as a desirable employer in the biotech industry.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

ABK Biomedical Inc. is a Halifax-based company founded in 2012 that specializes in developing embolotherapeutic products aimed at treating conditions such as uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing treatment options through innovative biomaterials, particularly by transforming the interventional radiology procedure known as embolization. ABK Biomedical has developed a novel radiopaque microsphere product that serves as a bland embolic agent, emitting beta radiation to improve targeting of tumor vascularity and tissue. This innovation aims to standardize, optimize, and personalize minimally invasive therapies for better patient outcomes.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

Elucidata Corporation, established in 2015 and based in New Delhi, India, specializes in accelerating drug discovery by translating phenotypic screenings into therapeutic strategies. The company's core offering is Polly, a proprietary SaaS platform that transforms drug discovery through curated biomedical molecular data. Polly hosts over 230,000 multi-omic datasets, with around 50,000 new datasets added monthly, and offers exclusive access to curated data ready for machine learning workflows. This platform enables 10x faster identification of therapeutic assets and has facilitated the detection of multiple validated drug targets across immunology, oncology, and metabolomic disorders. Polly supports discovery programs at prominent biopharma companies such as Pfizer, Agios Pharmaceuticals, Genentech, and Yale, with over 35 research partners from premier institutions.

RIGImmune is a biopharmaceutical company dedicated to developing innovative immune-modulating therapies targeting RNA virus diseases and enhancing antitumor immune responses. The company focuses on creating novel treatments aimed at addressing a wide range of conditions associated with viral infections and certain cancers. Its therapeutic candidates are designed to improve treatment outcomes for viral respiratory infections, serving as adjuvants or boosters for healthcare providers. By advancing its research and development efforts, RIGImmune aims to contribute significantly to the treatment landscape for both viral and oncological diseases.

Spry is a digital health platform that enables movement health professionals to collect and analyze patient data in real time. By leveraging machine learning and artificial intelligence, the platform provides personalized protocols based on evidence-based practices and standards of care. This allows practitioners and owners of physical therapy centers to effectively manage both clinical and administrative functions, enhancing the quality of patient care and operational efficiency.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

CHARM Therapeutics is a biotechnology company focused on delivering innovative medicines by leveraging advanced 3D deep learning and drug discovery technologies. Its platform is designed to address challenging disease targets that are typically considered undruggable, thereby enhancing treatment options for patients. By utilizing cutting-edge methodologies, CHARM Therapeutics aims to develop therapeutics with transformational efficacy, ultimately assisting healthcare professionals in improving patient outcomes.

SpectrumAi is a digital health company focused on enhancing Autism care by increasing access to high-quality Applied Behavior Analysis (ABA) therapy for children globally. By collaborating with industry experts in technology and healthcare, as well as clinical leaders, parents, and payers, SpectrumAi aims to modernize the delivery of autism care. The company's innovative healthcare technology offers objective data, meaningful insights, and actionable recommendations, all designed to support patients in achieving optimal outcomes. These outcomes include fostering independent living, building meaningful relationships, pursuing lifelong vocational goals, and promoting self-advocacy. Through its efforts, SpectrumAi seeks to transform the landscape of autism treatment and improve the quality of life for individuals on the spectrum.

Doceree Inc is a healthcare marketing technology company that operates a programmatic physician engagement and advertising platform. Founded in 2019 and based in Parsippany, New Jersey, with an additional office in New Delhi, India, Doceree connects pharmaceutical and healthcare brands with healthcare professionals (HCPs) through targeted advertising and data-driven solutions. The platform leverages artificial intelligence, data segmentation, and analytics to accurately identify and engage HCPs across various digital platforms, including physician networking sites and medical journals. By providing access to physician-only platforms, Doceree enables media agencies, pharmaceutical companies, medical device manufacturers, consumer healthcare brands, and hospitals to deliver compliant and effective messaging at scale.

Eleos Health is a technology company that specializes in artificial intelligence-driven solutions for the behavioral health sector. It has developed a voice technology platform designed to enhance clinicians' decision-making by providing real-time insights during mental health sessions. This AI-powered system operates in the background, analyzing voice interactions and other data parameters to generate valuable information about patients. By leveraging this technology, Eleos Health aims to facilitate personalized care, ensuring that mental health professionals can deliver timely and cost-effective support tailored to individual needs.

AmplifyMD is a telemedicine platform that bridges the gap between over 3,300 medical institutions, particularly in rural and underserved areas, and a network of specialized healthcare providers. The company develops a customized telehealthcare system that enables hospitals to access on-demand, remotely available specialists for various medical needs. By facilitating virtual care delivery and streamlining billing workflows, AmplifyMD helps reduce unnecessary patient transfers and lowers costs associated with temporary staffing solutions. The platform is designed to integrate seamlessly with existing electronic health records, enhancing the operational efficiency of healthcare facilities while improving patient access to specialized care.

Rialtic is a company that operates an open marketplace enterprise platform focused on enabling payers in the healthcare sector to achieve accurate payment processing. Its platform serves as a comprehensive reference source repository, providing curated content and advanced payment accuracy technology. This allows users to reduce costs associated with payment accuracy, adapt more easily to industry changes, and foster innovation in their payment processes. Through its offerings, Rialtic aims to streamline healthcare payments, making them more efficient and reliable for its clients.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Expressable is an online speech therapy practice dedicated to enhancing communication for individuals with speech and language disorders. It employs a parent-focused care model that integrates technology and educational resources, allowing families to incorporate speech therapy techniques into their daily routines. The platform offers a range of services, including support for accent modification, aphasia, apraxia of speech, autism spectrum disorder, and various language disorders. By providing tailored weekly practice activities, Expressable aims to improve speech and language outcomes for both children and adults, ensuring a more effective and accessible therapy experience.

K36 Therapeutics is a biotechnology company focused on developing small molecule therapeutics for cancer treatment. The company specializes in translating epigenetic modulation of oncogenic pathways into effective therapies. By leveraging advanced technology, K36 Therapeutics creates orally bioavailable small molecules and selective inhibitors, aiming to enhance the treatment options available to healthcare professionals and improve outcomes for cancer patients.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Galatea Bio is a biotechnology company based in the United States, founded by Carlos Bustamante, Nicholas Katsanis, and Alexander Ioannidis. The company focuses on improving diagnostic testing and accelerating drug discovery specifically for diverse and underserved populations that have historically been underrepresented in genetics research. Galatea Bio operates a biobank that serves as a biosample and bioinformatics platform, utilizing advanced algorithms and innovative analyses to facilitate genomic discoveries. Through its world-class clinical network, the company aims to identify patients at risk for severe multi-inflammatory syndromes or infections, ultimately working to develop new tests, treatments, and cures that enhance healthcare outcomes for all.

AppliedVR, Inc. is a Los Angeles-based company that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management in settings such as hospitals and surgery centers. Founded in 2013, AppliedVR has established strategic partnerships with institutions like Cedars-Sinai and Children's Hospital Los Angeles. The company's flagship product, EaseVRx, is a pioneering VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. This innovative treatment leverages principles of cognitive behavioral therapy and mindfulness to help patients manage chronic pain by changing their pain perception and fostering new coping skills. EaseVRx allows patients to self-administer therapy at home, facilitating remote care and improving access to effective pain management solutions. Through its clinically validated and comprehensive approach, AppliedVR seeks to address the complexities of chronic pain and enhance overall quality of life for patients.

Notable is an AI-driven platform designed to enhance healthcare operations by automating various workflows. With deployment at over 10,000 care sites, Notable automates more than a million repetitive tasks daily, including Registration and Intake, Scheduling and Referrals, and Authorizations. The platform features a voice-powered application that streamlines physician-patient interactions by structuring conversations, dictations, and orders, while also securely recommending billing codes. This automation not only facilitates personalized and efficient patient care but also alleviates the manual workload for healthcare providers, contributing to their financial health.

Patina Health operates a specialized primary care model focused on improving healthcare outcomes for older adults. Their approach prioritizes personalization, accessibility, and family involvement, aiming to enhance the aging experience by addressing the unique needs of this demographic.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

NOCD Inc. is a Chicago-based company founded in 2014 that specializes in developing a mobile application aimed at assisting individuals with obsessive-compulsive disorder (OCD). The platform connects users to licensed therapists who specialize in OCD through face-to-face video therapy sessions. Utilizing cognitive behavioral therapy techniques, the application guides users in self-treatment and monitoring of their symptoms, offering tools for exposure and response prevention exercises. In addition to therapy sessions, NOCD provides 24/7 support via self-help resources and peer communities, facilitating ongoing care and enabling patients to manage their condition effectively. The company focuses on improving treatment outcomes for OCD through its innovative online platform.

RareCyte, Inc. is a life sciences company based in Seattle, Washington, founded in 2009. The company specializes in developing advanced platforms for liquid and tissue biopsy analysis, focusing on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs) in blood samples. RareCyte's AccuCyte system provides an open platform that facilitates the unbiased discovery and isolation of these rare cells, supporting various applications in cancer research, cardiovascular disease studies, and diagnostic development. The company offers a range of products, including sample preparation systems, staining kits, automated fluorescence microscopy instruments, and slide imaging systems. By enabling precision medicine approaches, RareCyte aims to provide new tools for medical professionals and researchers to address complex questions in the fields of cancer and other therapeutic areas.

GYENNO Technologies is a digital health company developing medical devices for people with disabilities. GYENNO's products include GYENNO spoon, which helps people with hand tremors eat without stress, and the GYENNO matrix, a wearable motion and gait quantitative evaluation system for Parkinson's disease.

Oviva UK Limited, founded in 2013 and headquartered in London, offers digitally-enabled behavior change programs focused on diet and lifestyle-related health conditions, particularly type 2 diabetes and obesity. The company has developed a unique platform that combines a smartphone app with learning portals, enabling personalized behavior change programs led by qualified dietitians. This innovative approach allows patients to manage their health effectively without needing to attend in-person clinic appointments, thus reducing healthcare costs by preventing complications associated with these conditions. By providing tailored nutritional advice and coaching through technology, Oviva supports patients in achieving improved health outcomes.

SonderMind is a Denver-based digital health company established in 2017, specializing in accessible and approachable mental health services. It operates an online platform that connects individuals with a network of licensed therapists, offering a range of services including video telehealth and in-person sessions. SonderMind focuses on various mental health conditions such as anxiety, depression, ADHD, and PTSD, among others. The company aims to streamline the process of finding and accessing mental health care, ensuring a good match between clients and therapists, while also supporting therapists by handling administrative and billing tasks.

Embark offers dog DNA testing that ends preventable diseases in dogs. It was founded by top experts in genomics, computational biology, and software design to sell an industry-leading dog DNA test. They use a clinical-grade CLIA-certified SNP chip to provide the most accurate and comprehensive results (200,000+ genetic markers) available on the market. Their data contributes to proprietary genetics research that will help dog owners optimize nutrition, exercise, allergies, and prevent a variety of heritable conditions. Their technological advantage, intellectual capital, and research-focus enable them to push canine health toward our shared vision of preventative veterinary care.

Castor is an international health-tech company that provides a cloud-based clinical data platform designed to streamline the clinical trial process for researchers globally. Founded by CEO Derk Arts, MD, Ph.D., the platform is utilized by over 50,000 researchers in 90 countries, supporting more than 4,000 studies across diverse therapeutic areas, including diabetes, cardiovascular disease, rare diseases, infectious diseases, and oncology. Castor's platform facilitates the collection and analysis of extensive data from both traditional and remote trials, having reached significant milestones such as 180 million data points and 2 million enrolled patients. The company's mission is to make research data reusable, thereby enabling AI-driven clinical trials and enhancing the overall impact of data within the medical research community.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Zus Health is a healthcare technology company founded in 2020 by Jonathan Bush, based in Watertown, Massachusetts. It specializes in developing a healthcare data platform that accelerates the creation of digital health solutions. The platform uniquely integrates health and non-health information, allowing healthcare professionals to gain a comprehensive understanding of patients while sharing clinical and non-clinical data without requiring the same applications. By removing traditional barriers, Zus Health empowers a new generation of healthcare builders to design technologies and services that are more affordable and customizable, aiming to enhance the overall healthcare experience.

Protenus, Inc. is a healthcare compliance analytics company based in Baltimore, Maryland, which was founded in 2014. The company specializes in an AI-driven platform designed to audit access to patient records across health systems in the United States. Protenus' technology identifies risks such as inappropriate access to patient data and the misuse of controlled substances by healthcare staff. By automating the detection of policy violations and other anomalous behaviors, the platform supports healthcare organizations in protecting patient privacy and reducing operational risks. Protenus is recognized for its innovation and commitment to fostering safe patient outcomes while enhancing the reputation of healthcare providers. The company has received accolades such as being named one of America's Best Startup Employers by Forbes and recognized as a Great Place to Work.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options.

Proximie Inc., headquartered in Bedford, Massachusetts, operates a health technology platform that facilitates remote, real-time collaboration among surgeons worldwide. The company's core service enables surgeons to virtually attend operations via augmented reality, artificial intelligence, and machine learning technologies. This allows them to visually guide complex surgeries, demonstrate techniques, and provide expertise remotely, thereby democratizing access to advanced surgical knowledge globally. Founded by Nadine Hachach-Haram in 2016, Proximie aims to enhance surgical outcomes and improve patient care through innovative telehealth solutions.

1upHealth, Inc. is a health data aggregation and centralization company based in Boston, Massachusetts, founded in 2017. It operates a platform that enables patients, providers, and software developers to securely aggregate and share medical data from various electronic medical record systems. The platform consolidates health data into a digital health record that users can control and share with healthcare providers. It facilitates real-time access to updated patient information across multiple health systems, enhancing the ability of providers to deliver informed care. Additionally, the platform automates secure data sharing from electronic medical records and wearable device metrics, allowing for improved healthcare outcomes through a trusted interoperability network.

Zenflow, Inc. is a medical device company focused on developing innovative solutions for urinary obstruction caused by benign prostatic hyperplasia (BPH) in men. Founded in 2014 by a team of Stanford University Biodesign Fellows in collaboration with leading urologists, Zenflow aims to address the significant unmet clinical need for effective and less invasive treatments. The company markets a unique spring device designed to relieve permanent BPH symptoms by gently propping open the urethra, thereby restoring its normal function while preserving the natural anatomy. This approach prioritizes patient experience, offering a treatment option that is less invasive and less painful compared to traditional methods. Zenflow is headquartered in San Francisco, California.

Firefly Health, Inc. is a healthcare company based in Wellesley, Massachusetts, founded in 2016. It specializes in providing primary health care services through an artificial intelligence-based platform that connects patients with healthcare professionals. The company focuses on a virtual-first primary care approach, allowing users to access live video appointments with primary care physicians and care teams. This model emphasizes convenience and accessibility without membership fees, enabling patients to make informed decisions about their health. Firefly Health aims to redefine patient care by blending advanced technology with a dedicated care team to ensure continuous and proactive support for common health conditions, including back pain, stomach flu, and women's health issues.

AppliedVR, Inc. is a Los Angeles-based company that specializes in virtual reality solutions aimed at enhancing patient experiences in healthcare, particularly for pain and anxiety management in settings such as hospitals and surgery centers. Founded in 2013, AppliedVR has established strategic partnerships with institutions like Cedars-Sinai and Children's Hospital Los Angeles. The company's flagship product, EaseVRx, is a pioneering VR-based prescription therapeutic that has received Breakthrough Device Designation from the FDA. This innovative treatment leverages principles of cognitive behavioral therapy and mindfulness to help patients manage chronic pain by changing their pain perception and fostering new coping skills. EaseVRx allows patients to self-administer therapy at home, facilitating remote care and improving access to effective pain management solutions. Through its clinically validated and comprehensive approach, AppliedVR seeks to address the complexities of chronic pain and enhance overall quality of life for patients.

Genomics PLC is a company based in Oxford, United Kingdom, specializing in algorithms and software solutions that focus on cancer, microbes, and rare diseases. Founded in 2014, it aims to revolutionize healthcare through advanced analyses of extensive genomic and phenotypic datasets. By leveraging its expertise, the company provides healthcare providers and governments with tools to enhance patient diagnoses and treatment options. Additionally, Genomics assists pharmaceutical and biotechnology firms in mitigating risks during the drug development process by providing insights into genomic data. Its analytical platform facilitates the investigation of genomic sequences, helping to identify individuals at risk of various diseases. Through these innovations, Genomics seeks to set standards in the use of genomic data, ultimately aiming to improve healthcare outcomes and advance human biology understanding.

Yisheng Biopharma Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and marketing of immuno-oncology products and vaccines. Founded in 2002 and headquartered in Beijing, the company operates in China, the United States, Cambodia, and Singapore. Yisheng Biopharma utilizes its novel PIKA immunomodulating technology to enhance immune responses against cancers and infectious diseases. Key products under development include YS-ON-001, an investigational therapy aimed at treating advanced solid tumors, as well as YS-HBV-001, a vaccine for hepatitis B, and a PIKA-based rabies vaccine designed for rapid protection against rabies infection. The company's innovative approach targets multiple immune pathways to improve treatment outcomes.

Cohort, Inc. is a software company focused on enhancing chronic care management and clinical trial processes. Based in New York with an additional office in San Francisco, the company utilizes clinical artificial intelligence and natural language processing to analyze electronic health records. This analysis includes evaluating diagnostics, medications, and clinical notes to provide context relevant to specific patients and their conditions. Cohort’s software streamlines the identification and enrollment of eligible patients, generates tailored care plans, and automates compliance and billing tasks. The company’s solutions are designed to enable Primary Care Providers to improve the scale, efficiency, and outcomes of their Chronic Care Management programs while facilitating clinical trial identification and enrollment.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Hurdle Health, Inc., established in 2020 and based in Washington, D.C., specializes in culturally intentional mental health services. The company operates a digital platform that connects diverse individuals, couples, and families with appropriate therapists, offering a suite of teletherapy services and self-mastery tools. Hurdle's approach is tailored to meet the unique needs of underserved populations, providing culturally responsive care for a wide range of stressors. The platform aims to create a safe and understanding space for patients, focusing on serving the BIPOC community and other minority groups.

Metcela Inc., founded in 2016 and based in Kawasaki-shi, Japan, is a clinical-stage biotech company focused on developing innovative therapies for cardiac diseases. The company specializes in fibroblast-based treatments, particularly utilizing VCAM-1-positive Cardiac Fibroblasts (VCF). Metcela's lead asset, MTC001, aims to repair damaged heart tissues and reestablish a favorable microenvironment by enhancing the healing capabilities of the patient's own cells. This approach provides an alternative treatment option for heart disease, offering patients an effective and cost-efficient solution for conditions like heart failure.

Centivo Corporation is a health insurance provider that specializes in offering innovative health plans for self-funded employers, employees, and clinicians. Established in 2016 and headquartered in Stamford, Connecticut, with additional offices in New York and Buffalo, Centivo serves as an alternative to traditional insurance carriers and third-party administrators. The company integrates technology, network management, claims processing, and customer support to effectively administer health benefits. Centivo emphasizes collaboration between employees and their primary care teams to coordinate healthcare needs, encouraging members to engage in high-value care through personalized matching tools and a user-friendly app. By focusing on controlling costs and improving navigation through the healthcare system, Centivo positions itself as a dedicated partner to employers, ensuring accountability and minimizing waste in healthcare spending.

WellAir Group Limited, founded in 2012 and based in Dublin, Ireland, specializes in designing and manufacturing portable air disinfection units and HVAC air purification devices. The company aims to improve indoor air quality by eliminating airborne pollutants and pathogens, including viruses, bacteria, allergens, and mold. Its products, marketed under the Novaerus and Plasma-Air brands, serve a variety of sectors such as healthcare, senior living, education, and industry. WellAir's offerings include medical-grade air disinfection units that deactivate airborne pathogens and neutralize volatile organic compounds, as well as HVAC systems utilizing plasma-generated bipolar ionization to reduce particulate matter and odors. Additionally, WellAir develops sensors and a web-based monitoring portal that tracks outdoor air pollution and other environmental factors, contributing to safer indoor environments and promoting public health.

Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

Verve Therapeutics is a genetic medicines company based in Cambridge, Massachusetts, focused on innovative therapies for cardiovascular disease. Founded in 2018, the company aims to transform the management of cardiovascular conditions from chronic treatments to single-course gene editing medicines. Verve Therapeutics employs advanced gene-editing technology and human genetic analysis to develop targeted therapies that reduce the risk of coronary artery diseases. Its initial programs focus on the PCSK9 and ANGPTL3 genes, which are crucial for lowering harmful blood lipids like low-density lipoprotein cholesterol. The company collaborates with strategic partners, including Beam Therapeutics for delivery technologies and Verily for gene editing delivery vehicles, enhancing its capabilities in the biotechnology and healthcare sectors.

PatientPing, Inc. is a health technology company that has developed a national care coordination network aimed at enhancing communication among healthcare providers. Founded in 2013 and headquartered in Boston, Massachusetts, the company offers real-time notifications and care guidelines to various healthcare professionals, including physicians, nurses, case managers, and care coordinators. This network spans hospitals, emergency departments, accountable care organizations, physician practices, skilled nursing facilities, home health agencies, and payers. PatientPing's platform includes a tool called Spotlights, which leverages real-time data to analyze utilization and performance trends in patient care. By improving information sharing among care teams, PatientPing facilitates higher quality, cost-effective care, ultimately aiming to enhance patient outcomes and experiences. The company also maintains a strategic partnership with MedAllies, Inc. and operates as a subsidiary of SVB Leerink Holdings LLC.

NodThera Limited is a biotechnology company engaged in the research and development of novel inhibitors targeting the NLRP3 inflammasome to address various inflammatory and neuroinflammatory diseases. Founded in 2016 and headquartered in Little Chesterford, United Kingdom, with additional facilities in Seattle, Washington, and a corporate office in Lexington, Massachusetts, NodThera focuses on creating therapies for conditions such as arthritis, atherosclerosis, Alzheimer’s disease, diabetes, and certain cancers. The company's drug development pipeline includes potent and selective NLRP3 inflammasome inhibitors designed to reduce pro-inflammatory cytokines associated with chronic inflammation, thereby enhancing treatment options for patients suffering from these chronic diseases.

Owkin, Inc. is an artificial intelligence company that specializes in developing software aimed at improving treatment outcomes for patients, particularly in oncology. Established in 2016, with headquarters in New York and an office in Paris, Owkin employs AI tools to enhance drug discovery and accelerate clinical trials while safeguarding patient privacy through federated learning. The company offers several products, including Owkin Lab for therapeutic data connection, Owkin Loop for validated and packaged models, and a comprehensive software stack. Owkin's portfolio includes 30 live models, with an additional 40 in development, focusing on identifying new drug candidates and elucidating the mechanisms behind treatment efficacy. Co-founded by Thomas Clozel, a clinical research doctor, and Gilles Wainrib, a machine learning expert, Owkin has raised over $255 million and achieved unicorn status due to its innovative approach in addressing unmet medical needs and optimizing the drug development process.

Avalyn Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies for idiopathic pulmonary fibrosis (IPF) and other serious respiratory conditions. Headquartered in Seattle, Washington, with an additional office in San Diego, the company specializes in an inhaled formulation of pirfenidone, known as AP01. This formulation aims to enhance the amount of medication that reaches the lungs while minimizing side effects associated with oral treatments. Established in 2011, Avalyn Pharma is dedicated to improving care and outcomes for patients with severe respiratory diseases through its advanced therapeutic pipeline and novel inhaled therapeutics. Initially named Genoa Pharmaceuticals, the company rebranded to its current name in July 2017.

SonderMind is a Denver-based digital health company established in 2017, specializing in accessible and approachable mental health services. It operates an online platform that connects individuals with a network of licensed therapists, offering a range of services including video telehealth and in-person sessions. SonderMind focuses on various mental health conditions such as anxiety, depression, ADHD, and PTSD, among others. The company aims to streamline the process of finding and accessing mental health care, ensuring a good match between clients and therapists, while also supporting therapists by handling administrative and billing tasks.

Affinia Therapeutics Inc. is a biotechnology company focused on developing gene therapies for the treatment of severe diseases affecting the muscle and central nervous system (CNS). Established in 2019 and based in Waltham, Massachusetts, the company specializes in creating adeno-associated virus (AAV) vectors and utilizes a platform that integrates synthetic and systems biology with high-throughput screening techniques. This innovative approach allows Affinia Therapeutics to design novel gene therapies with enhanced properties tailored to address significant unmet medical needs. The company aims to provide healthcare professionals with advanced therapeutic options for patients suffering from debilitating conditions.

B-One Ortho Corp. is a manufacturer of orthopedic healthcare solutions, specializing in artificial joints that facilitate joint replacement surgeries. Founded in 2015 and headquartered in Cedar Knolls, New Jersey, the company also maintains offices in Shanghai and Suzhou, China. Its notable products include the B-One total hip system, which features advanced coating technology and instrumentation, as well as the Juveno bone-conserving femoral prosthesis and primary acetabular systems. These innovations aim to enhance the effectiveness of hip and knee arthroplasty, ultimately helping patients regain their mobility and improve their quality of life.

Xilio Therapeutics is a clinical-stage biotechnology company focused on developing innovative immunotherapies to enhance the immune system's ability to combat cancer. The company specializes in tumor-selective immunotherapies, utilizing its proprietary technology to maximize the effectiveness of immuno-oncology treatments while minimizing side effects outside the tumor. Among its key products is XTX201, which aims to induce immune activity directly within tumors, demonstrating improved antitumor effects. Founded in 2015 and based in Waltham, Massachusetts, Xilio Therapeutics was previously known as Akrevia Therapeutics until its rebranding in March 2020. The company is dedicated to advancing a pipeline of novel immuno-oncology molecules, including tumor-activated cytokines and antibodies, with the goal of significantly improving patient outcomes in cancer treatment.

WelbeHealth is a healthcare organization dedicated to serving frail seniors through the Program of All-Inclusive Care for the Elderly (PACE). The company provides a comprehensive model of medical and social care, enabling elderly participants to live healthier, longer, and more independent lives. Founded by experienced physician entrepreneurs, WelbeHealth's leadership team has backgrounds in prominent payer and provider organizations. The company coordinates all aspects of care for its participants, including medical and dental services, therapy, transportation, and meal provision, ensuring a fully integrated approach to health management. By focusing on quality, compassion, and value, WelbeHealth aims to enhance the lives of vulnerable seniors in the community.

Oviva UK Limited, founded in 2013 and headquartered in London, offers digitally-enabled behavior change programs focused on diet and lifestyle-related health conditions, particularly type 2 diabetes and obesity. The company has developed a unique platform that combines a smartphone app with learning portals, enabling personalized behavior change programs led by qualified dietitians. This innovative approach allows patients to manage their health effectively without needing to attend in-person clinic appointments, thus reducing healthcare costs by preventing complications associated with these conditions. By providing tailored nutritional advice and coaching through technology, Oviva supports patients in achieving improved health outcomes.

Adagene is a clinical-stage biotechnology company focused on developing immuno-oncology antibodies targeting novel epitopes. The company utilizes its proprietary Smart Antibody Technology to enhance the success rates of antibody development, significantly expedite the time to market, and lower the associated costs of creating therapeutic antibodies. Adagene is actively engaged in the research, development, and production of monoclonal antibody drugs aimed at treating various types of cancer. Its innovative platform is designed to generate therapeutic antibody candidates that exhibit functional epitopes and species cross-reactivity, underscoring the potential impact of its immunotherapy pipeline in addressing cancer treatment challenges.

AviadoBio is a biotechnology company focused on developing transformative gene therapies for neurodegenerative disorders, specifically targeting diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company leverages innovative research from King’s College London and the UK Dementia Research Institute to create its therapeutic platform. By integrating a deep understanding of brain biology with proprietary gene therapies, AviadoBio aims to effectively address the challenges of delivering treatments to the appropriate areas within the nervous system. The ultimate goal is to enhance the therapeutic potential of gene therapy, potentially halting or even reversing the progression of these debilitating conditions, thereby improving the quality of life for affected individuals.

Immuneel Therapeutics specializes in developing innovative cell and gene therapies for cancer treatment. The company focuses on CAR-T cell therapies, which are created by extracting blood cells from patients and genetically engineering healthy immune cells to specifically target malignant cells. This approach allows cancer patients to benefit from advanced cell-based immunotherapies that have the potential to transform their treatment outcomes.

Equip is a virtual program helping families recover from eating disorders at home with comprehensive, gold-standard care created by experts in the field and people in recovery. Equip’s five-person care teams include dieticians, physicians, therapists, and mentors who deliver wrap-around support to provide families progress and lasting recovery. Kristina Saffran and Erin Parks co-founded the company in San Diego, California in 2019.

Medbanks Network Technology, based in Beijing and founded in 2014, specializes in data processing services tailored for the healthcare sector. The company focuses on developing an oncology database that consolidates clinical and professional medical services, leveraging information collected from hospitals. This initiative enhances the availability of critical data for healthcare providers and researchers. Medbanks plays a significant role in supporting the healthcare industry's need for accurate and comprehensive medical information, thereby contributing to advancements in patient care and treatment methodologies.

Wellframe Inc. is a Boston-based company that specializes in digital care management and health advocacy solutions. Founded in 2011, it partners with health plans across the country to enhance the relationship between healthcare providers and members. Wellframe's offerings include a mobile application that facilitates daily health reporting, a care team dashboard to prioritize patient needs, and an array of communication tools for two-way messaging. The company also provides comprehensive operational services, such as implementation support, recruiting, and analytics. Additionally, Wellframe's platform employs real-time data and artificial intelligence to deliver personalized care protocols, enabling caregivers to monitor patient status effectively and identify when intervention is necessary. By focusing on mobile patient engagement and care management, Wellframe aims to improve health outcomes and empower individuals in managing their health.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.